Innovative Vaccine Performance
Design-Zyme is a boutique biotech developing cutting-edge vaccines designed from inception to be safe. Our platform addresses contemporary challenges and offers effective solutions to human health challenges. Design-Zyme's pipeline includes novel solutions for opioid use disorder (OUD) and Lyme Disease. Our platform is currently being extended to Chlamydia and other pathogenic threats to human health. We have also developed a novel, patented adjuvant solution based on naturally occurring carbohydrates that allows for additional, effective routes of administration, including oral and nasal delivery.
Next-Gen Vaccines
We have developed new approaches for hapten-based vaccines for Opioid Use Disorder as well as multivalent nanoparticle approaches to combat Lyme Disease.
Data-Driven Research
Our vaccine development efforts are based on data-driven research, ensuring that our vaccines meet rigorous FDA standards for safety and efficacy.
Expert Team
Our team of experts in protein engineering, biochemical analysis, carbohydrate chemistry, and immunology brings together extensive experience to drive our research and development efforts.
Novel Adjuvant Solutions
Our natural adjuvant solutions are carbohydrate-based allowing for safe and effective vaccine delivery via a variety of administration routes including oral, nasal and mucosal.
Versatile Technology
Our antibody solutions are custom designed to meet a range of criteria to ensure that our vaccines are modular and capable of eliciting a range of antibodies to address multivalent threats. This ensures that our vaccines result in strong immune responses to a wide range of pathogens and compounds.
Who we are
We are a team of scientists, health care professionals, and innovators that are dedicated to developing the next generation of safe, effective, and multifaceted vaccines to meet the needs of patients and the medical community. A rigorous, data-first research and development approach paired with modern technologies power our pipeline and accelerate decision-making from discovery to development.
2
Vaccines in Development
9M
Funding Raised
​
3
Patents Allowed
​
11
Patents Pending
​
9
Publications
​
Our Partners
